To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

PHASE2RecruitingINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

January 17, 2023

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2029

Conditions
Advanced Solid Tumors
Interventions
DRUG

Vabametkib

"Tablets~Route of Administration: Oral"

DRUG

Lazertinib

"Tablets~Route of Administration: Oral"

Trial Locations (24)

100

RECRUITING

National Taiwan University Hospital, Taipei

112

RECRUITING

Taipei Veterans General Hospital, Taipei

404

RECRUITING

China Medical University Hospital, Taichung

704

RECRUITING

National Cheng Kung University Hospital, Tainan City

736

RECRUITING

Chi Mei Hospital, Liouying, Tainan City

10052

RECRUITING

National Taiwan University Cancer Center (NTUCC), Taipei

10408

RECRUITING

National Cancer Center, Goyang-si

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

16248

RECRUITING

The Catholic University of Korea St Vincents Hospital, Suwon

16499

RECRUITING

Ajou University Hospital, Suwon

21565

RECRUITING

Gachon University Gil Medical Center, Incheon

28645

RECRUITING

Chungbuk National University Hospital, Cheongju-si

48202

NOT_YET_RECRUITING

The Henry Ford Cancer Institute, Detroit

52728

RECRUITING

Gyeongsang National University Hospital, Jinju

32024-3456

RECRUITING

Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology, Lake City

32763-8316

RECRUITING

Mid Florida Center, Orange City

77030-4000

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

07061

RECRUITING

Boramae Medical Center, Dongjak

02841

RECRUITING

Korea University Anam Hospital, Seoul

03776

RECRUITING

Severance Hospital, Sinchon-dong

03181

RECRUITING

Kangbuk Samsung Hospital, Seoul

05505

RECRUITING

Asan Medical Center, Seoul

06351

RECRUITING

Samsung Medical Center, Seoul

06591

RECRUITING

The Catholic University of Korea, Seoul St Mary's Hospitals, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abion Inc

INDUSTRY

NCT05541822 - To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | Biotech Hunter | Biotech Hunter